S&P 500   3,337.35 (-0.35%)
DOW   27,316.70 (-0.26%)
QQQ   270.00 (-1.69%)
AAPL   442.68 (-2.84%)
MSFT   211.40 (-2.29%)
FB   266.46 (+0.44%)
GOOGL   1,489.76 (-1.01%)
AMZN   3,148.07 (-2.39%)
NVDA   442.07 (-2.50%)
CGC   16.68 (-4.79%)
BABA   250.52 (-5.71%)
TSLA   1,422.12 (-4.53%)
MU   48.21 (-1.01%)
GE   6.39 (+0.95%)
AMD   83.47 (-3.74%)
T   29.94 (+0.34%)
F   6.84 (-1.30%)
ACB   10.09 (-2.13%)
GILD   68.95 (+0.20%)
NFLX   488.08 (-4.13%)
DIS   129.42 (-1.07%)
BAC   26.01 (+2.12%)
BA   169.33 (-1.67%)
S&P 500   3,337.35 (-0.35%)
DOW   27,316.70 (-0.26%)
QQQ   270.00 (-1.69%)
AAPL   442.68 (-2.84%)
MSFT   211.40 (-2.29%)
FB   266.46 (+0.44%)
GOOGL   1,489.76 (-1.01%)
AMZN   3,148.07 (-2.39%)
NVDA   442.07 (-2.50%)
CGC   16.68 (-4.79%)
BABA   250.52 (-5.71%)
TSLA   1,422.12 (-4.53%)
MU   48.21 (-1.01%)
GE   6.39 (+0.95%)
AMD   83.47 (-3.74%)
T   29.94 (+0.34%)
F   6.84 (-1.30%)
ACB   10.09 (-2.13%)
GILD   68.95 (+0.20%)
NFLX   488.08 (-4.13%)
DIS   129.42 (-1.07%)
BAC   26.01 (+2.12%)
BA   169.33 (-1.67%)
S&P 500   3,337.35 (-0.35%)
DOW   27,316.70 (-0.26%)
QQQ   270.00 (-1.69%)
AAPL   442.68 (-2.84%)
MSFT   211.40 (-2.29%)
FB   266.46 (+0.44%)
GOOGL   1,489.76 (-1.01%)
AMZN   3,148.07 (-2.39%)
NVDA   442.07 (-2.50%)
CGC   16.68 (-4.79%)
BABA   250.52 (-5.71%)
TSLA   1,422.12 (-4.53%)
MU   48.21 (-1.01%)
GE   6.39 (+0.95%)
AMD   83.47 (-3.74%)
T   29.94 (+0.34%)
F   6.84 (-1.30%)
ACB   10.09 (-2.13%)
GILD   68.95 (+0.20%)
NFLX   488.08 (-4.13%)
DIS   129.42 (-1.07%)
BAC   26.01 (+2.12%)
BA   169.33 (-1.67%)
S&P 500   3,337.35 (-0.35%)
DOW   27,316.70 (-0.26%)
QQQ   270.00 (-1.69%)
AAPL   442.68 (-2.84%)
MSFT   211.40 (-2.29%)
FB   266.46 (+0.44%)
GOOGL   1,489.76 (-1.01%)
AMZN   3,148.07 (-2.39%)
NVDA   442.07 (-2.50%)
CGC   16.68 (-4.79%)
BABA   250.52 (-5.71%)
TSLA   1,422.12 (-4.53%)
MU   48.21 (-1.01%)
GE   6.39 (+0.95%)
AMD   83.47 (-3.74%)
T   29.94 (+0.34%)
F   6.84 (-1.30%)
ACB   10.09 (-2.13%)
GILD   68.95 (+0.20%)
NFLX   488.08 (-4.13%)
DIS   129.42 (-1.07%)
BAC   26.01 (+2.12%)
BA   169.33 (-1.67%)
Log in

NASDAQ:ARAVAravive Stock Price, Forecast & News

$5.98
+0.41 (+7.36 %)
(As of 08/7/2020 02:57 PM ET)
Add
Compare
Today's Range
$5.47
Now: $5.98
$6.24
50-Day Range
$5.89
MA: $10.70
$14.81
52-Week Range
$3.34
Now: $5.98
$15.62
Volume25,410 shs
Average Volume271,900 shs
Market Capitalization$95.80 million
P/E RatioN/A
Dividend YieldN/A
Beta3.22
Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARAV
CUSIPN/A
CIKN/A
Phone936-355-1910

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.75 million
Book Value$3.71 per share

Profitability

Net Income$-18,220,000.00

Miscellaneous

Employees14
Market Cap$95.80 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$5.98
+0.41 (+7.36 %)
(As of 08/7/2020 02:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARAV News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aravive (NASDAQ:ARAV) Frequently Asked Questions

How has Aravive's stock been impacted by COVID-19 (Coronavirus)?

Aravive's stock was trading at $4.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARAV shares have increased by 19.8% and is now trading at $5.98.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Aravive?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aravive
.

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Aravive
.

How were Aravive's earnings last quarter?

Aravive Inc (NASDAQ:ARAV) posted its earnings results on Monday, August, 3rd. The company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.14.
View Aravive's earnings history
.

What price target have analysts set for ARAV?

5 equities research analysts have issued 1-year price objectives for Aravive's shares. Their forecasts range from $26.00 to $31.00. On average, they expect Aravive's stock price to reach $28.75 in the next twelve months. This suggests a possible upside of 380.8% from the stock's current price.
View analysts' price targets for Aravive
.

Has Aravive been receiving favorable news coverage?

Media coverage about ARAV stock has trended positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aravive earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Aravive
.

Are investors shorting Aravive?

Aravive saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 1,020,000 shares, an increase of 15.5% from the July 15th total of 883,400 shares. Based on an average daily trading volume, of 180,700 shares, the days-to-cover ratio is presently 5.6 days. Currently, 11.4% of the shares of the company are short sold.
View Aravive's Current Options Chain
.

Who are some of Aravive's key competitors?

What other stocks do shareholders of Aravive own?

Who are Aravive's key executives?

Aravive's management team includes the following people:
  • Mr. Jay P. Shepard, Pres, CEO & Director (Age 61)
  • Dr. Jeffrey L. Cleland, Co-Founder (Age 54)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Mr. Vinay Shah, Chief Financial Officer
  • Dr. Gail F. McIntyre, Chief Scientific Officer (Age 56)

What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Who are Aravive's major shareholders?

Aravive's stock is owned by a number of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.17%), Alps Advisors Inc. (0.14%) and New York State Common Retirement Fund (0.07%). Company insiders that own Aravive stock include Jay Shepard, Kevin Haas and Srinivas Akkaraju.
View institutional ownership trends for Aravive
.

Which institutional investors are buying Aravive stock?

ARAV stock was purchased by a variety of institutional investors in the last quarter, including Alps Advisors Inc., New York State Common Retirement Fund, and Wedbush Securities Inc..
View insider buying and selling activity for Aravive
.

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $5.98.

How big of a company is Aravive?

Aravive has a market capitalization of $95.80 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 14 workers across the globe.

What is Aravive's official website?

The official website for Aravive is www.aravive.com.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.